Consumer Reps Join ODAC Meetings

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

ROCKVILLE, Md--In February, as part of an FDA pilot program, representatives of consumer groups sat at the table during an Oncologic Drugs Advisory Committee (ODAC) meeting. The ad hoc representatives from the Treatment Action Group, a New York organization representing people with AIDS, and the National Breast Cancer Coalition participated in the discussions of New Drug Applications but did not have a vote.

ROCKVILLE, Md--In February, as part of an FDA pilot program, representativesof consumer groups sat at the table during an Oncologic DrugsAdvisory Committee (ODAC) meeting. The ad hoc representativesfrom the Treatment Action Group, a New York organization representingpeople with AIDS, and the National Breast Cancer Coalition participatedin the discussions of New Drug Applications but did not have avote.

According to Randy Wykoff, MD, FDA associate commissioner forAIDS and special health issues, the pilot program is a responseto requests from cancer advocacy groups. Different representativeswill be chosen for each NDA that ODAC reviews. ODAC often asksnon-voting medical and /or scientific consultants to help reviewNDAs; consumer advocates would serve a simular function, Dr. Wykoffsaid.

Recent Videos
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Related Content